The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
Multiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains incurable despite the therapeutic armamentarium’s evolution. Bispecific antibodies (BsAbs) can bind simultaneously to the CD3 T-cell receptor and tumor antigen of myeloma cells, causing cell lysis. This systemat...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/12/2/38 |
| _version_ | 1827738876230238208 |
|---|---|
| author | Razwana Khanam Omer S. Ashruf Syed Hamza Bin Waqar Zunairah Shah Saba Batool Rameesha Mehreen Pranali Pachika Zinath Roksana Mohammad Ebad Ur Rehman Faiz Anwer |
| author_facet | Razwana Khanam Omer S. Ashruf Syed Hamza Bin Waqar Zunairah Shah Saba Batool Rameesha Mehreen Pranali Pachika Zinath Roksana Mohammad Ebad Ur Rehman Faiz Anwer |
| author_sort | Razwana Khanam |
| collection | DOAJ |
| description | Multiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains incurable despite the therapeutic armamentarium’s evolution. Bispecific antibodies (BsAbs) can bind simultaneously to the CD3 T-cell receptor and tumor antigen of myeloma cells, causing cell lysis. This systematic review of phase I/II/III clinical trials aimed to analyze the efficacy and safety of BsAbs in relapsed refractory multiple myeloma (RRMM). A thorough literature search was performed using PubMed, Cochrane Library, EMBASE, and major conference abstracts. A total of 18 phase I/II/III studies, including 1283 patients, met the inclusion criteria. Among the B-cell maturation antigen (BCMA)-targeting agents across 13 studies, the overall response rate (ORR) ranged between 25% and 100%, with complete response/stringent complete response (CR/sCR) between 7 and 38%, very good partial response (VGPR) between 5 and 92%, and partial response (PR) between 5 and 14%. Among the non-BCMA-targeting agents across five studies, the ORR ranged between 60 and 100%, with CR/sCR seen in 19–63%, and VGPR in 21–65%. The common adverse events were cytokine release syndrome (17–82%), anemia (5–52%), neutropenia (12–75%), and thrombocytopenia (14–42%). BsAbs have shown promising efficacy against RRMM cohorts with a good safety profile. Upcoming phase II/III trials are much awaited, along with the study of other agents in concert with BsAbs to gauge response. |
| first_indexed | 2024-03-11T02:51:13Z |
| format | Article |
| id | doaj.art-e6d24d4e2f7649d999ab87e94523acff |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-03-11T02:51:13Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-e6d24d4e2f7649d999ab87e94523acff2023-11-18T09:01:56ZengMDPI AGAntibodies2073-44682023-05-011223810.3390/antib12020038The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic ReviewRazwana Khanam0Omer S. Ashruf1Syed Hamza Bin Waqar2Zunairah Shah3Saba Batool4Rameesha Mehreen5Pranali Pachika6Zinath Roksana7Mohammad Ebad Ur Rehman8Faiz Anwer9Department of Hospital Medicine, Baystate Medical Center, Springfield, MA 01199, USACollege of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USADownstate Medical Center, Department of Internal Medicine, State University of New York (SUNY), Brooklyn, NY 11203, USADepartment of Internal Medicine, Louis A Weiss Memorial Hospital, Chicago, IL 60640, USADepartment of Hospital Medicine, Unity Point Methodist Hospital, Peoria, IL 61636, USADepartment of Internal Medicine, Jefferson Abington Hospital, Abington, PA 19001, USADepartment of Hematology-Oncology, University of Louisville, Louisville, KY 40202, USAMedical Officer, Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka 1217, BangladeshDepartment of Medicine, Rawalpindi Medical University, Rawalpindi 46000, PakistanDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USAMultiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains incurable despite the therapeutic armamentarium’s evolution. Bispecific antibodies (BsAbs) can bind simultaneously to the CD3 T-cell receptor and tumor antigen of myeloma cells, causing cell lysis. This systematic review of phase I/II/III clinical trials aimed to analyze the efficacy and safety of BsAbs in relapsed refractory multiple myeloma (RRMM). A thorough literature search was performed using PubMed, Cochrane Library, EMBASE, and major conference abstracts. A total of 18 phase I/II/III studies, including 1283 patients, met the inclusion criteria. Among the B-cell maturation antigen (BCMA)-targeting agents across 13 studies, the overall response rate (ORR) ranged between 25% and 100%, with complete response/stringent complete response (CR/sCR) between 7 and 38%, very good partial response (VGPR) between 5 and 92%, and partial response (PR) between 5 and 14%. Among the non-BCMA-targeting agents across five studies, the ORR ranged between 60 and 100%, with CR/sCR seen in 19–63%, and VGPR in 21–65%. The common adverse events were cytokine release syndrome (17–82%), anemia (5–52%), neutropenia (12–75%), and thrombocytopenia (14–42%). BsAbs have shown promising efficacy against RRMM cohorts with a good safety profile. Upcoming phase II/III trials are much awaited, along with the study of other agents in concert with BsAbs to gauge response.https://www.mdpi.com/2073-4468/12/2/38bispecific antibodiesrelapsed refractory multiple myelomateclistamabelranatambtalquetamab |
| spellingShingle | Razwana Khanam Omer S. Ashruf Syed Hamza Bin Waqar Zunairah Shah Saba Batool Rameesha Mehreen Pranali Pachika Zinath Roksana Mohammad Ebad Ur Rehman Faiz Anwer The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review Antibodies bispecific antibodies relapsed refractory multiple myeloma teclistamab elranatamb talquetamab |
| title | The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review |
| title_full | The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review |
| title_fullStr | The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review |
| title_full_unstemmed | The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review |
| title_short | The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review |
| title_sort | role of bispecific antibodies in relapsed refractory multiple myeloma a systematic review |
| topic | bispecific antibodies relapsed refractory multiple myeloma teclistamab elranatamb talquetamab |
| url | https://www.mdpi.com/2073-4468/12/2/38 |
| work_keys_str_mv | AT razwanakhanam theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT omersashruf theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT syedhamzabinwaqar theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT zunairahshah theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT sababatool theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT rameeshamehreen theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT pranalipachika theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT zinathroksana theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT mohammadebadurrehman theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT faizanwer theroleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT razwanakhanam roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT omersashruf roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT syedhamzabinwaqar roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT zunairahshah roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT sababatool roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT rameeshamehreen roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT pranalipachika roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT zinathroksana roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT mohammadebadurrehman roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview AT faizanwer roleofbispecificantibodiesinrelapsedrefractorymultiplemyelomaasystematicreview |